Given the relatively low rate of mutations caused by estrogen at physiologic concentrations and the few consistent mutations identified in clinical prostate cancer, it is likely that future ...

OncoAssure Ltd, an Irish medical diagnostic company, announced the publication of new data in the journal BJUI Compass that demonstrate the clinical validation of OncoAssure Prostate, a novel ...

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

The study demonstrated that integrating OncoAssure Prostate results with standard clinical and pathological information can substantially improve prognostic accuracy. Patients with higher ...

In this Review we discuss the current knowledge on the use of statins to prevent prostate cancer. We will also look at future directions for clinical research on this topic. Introduction of the ...